Polyuria: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(51 intermediate revisions by 10 users not shown) | |||
Line 2: | Line 2: | ||
{| class="infobox" style="float:right;" | {| class="infobox" style="float:right;" | ||
|- | |- | ||
| [[File:Siren.gif | | [[File:Siren.gif|link=Polyuria resident survival guide|41x41px]]|| <br> || <br> | ||
| [[Polyuria resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | | [[Polyuria resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | ||
|} | |} | ||
{{Search infobox}} | {{Search infobox}} | ||
''' | {{CMG}}; {{AE}} {{ADS}} {{LRO}}, Roshan Dinparasti Saleh M.D.<br><br>'''To view a comprehensive algorithm of common findings of urine composition and urine output, click [[Urine#Algorithm of Common Urinary Findings|here]]'''<br> | ||
==Overview== | ==Overview== | ||
Polyuria is the passage of a large volume of [[urine]] in a given period (>= 2.5L/24 hours in adult humans). It often appears with increased thirst ([[polydipsia]]). Various causes of polyuria include | |||
==Causes== | |||
# '''Central diabetes inispidus''' (CDI) | |||
## Idiopathic CDI: the most common cause of CDI<ref name="lymphoma">Kimmel DW, O'Neill BP: Systemic cancer presenting as diabetes insipidus. Clinical and radiographic features of 11 patients with a review of metastatic-induced diabetes insipidus. Cancer 1983, 52(12):2355-2358.</ref><ref>Maghnie M, Cosi G, Genovese E, Manca-Bitti ML, Cohen A, Zecca S, Tinelli C, Gallucci M, Bernasconi S, Boscherini B et al: Central diabetes insipidus in children and young adults. The New England journal of medicine 2000, 343(14):998-1007.</ref> | |||
## Familial CDI<ref>Christensen JH, Rittig S: Familial neurohypophyseal diabetes insipidus--an update. Seminars in nephrology 2006, 26(3):209-223.</ref> | |||
## [[Wolfram syndrome]] ( DIDOMAD syndrome)<ref>Bischoff AN, Reiersen AM, Buttlaire A, Al-Lozi A, Doty T, Marshall BA, Hershey T: Selective cognitive and psychiatric manifestations in Wolfram Syndrome. Orphanet journal of rare diseases 2015, 10:66.</ref> | |||
## Congenital [[hypopituitarism]]<ref>Lukezic M, Righini V, Di Natale B, De Angelis R, Norbiato G, Bevilacqua M, Chiumello G: Vasopressin and thirst in patients with posterior pituitary ectopia and hypopituitarism. Clinical endocrinology 2000, 53(1):77-83.</ref> | |||
## [[Septo-optic dysplasia]]<ref>Hoyt WF, Kaplan SL, Grumbach MM, Glaser JS: Septo-optic dysplasia and pituitary dwarfism. Lancet (London, England) 1970, 1(7652):893-894.</ref> | |||
## [[Surgery]]/[[trauma]]<ref>Nemergut EC, Zuo Z, Jane JA, Jr., Laws ER, Jr.: Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. Journal of neurosurgery 2005, 103(3):448-454.</ref> | |||
## [[Cancer]] ([[lung cancer]], [[leukemia]], [[lymphoma]])<ref name="lymphoma">Kimmel DW, O'Neill BP: Systemic cancer presenting as diabetes insipidus. Clinical and radiographic features of 11 patients with a review of metastatic-induced diabetes insipidus. Cancer 1983, 52(12):2355-2358.</ref> | |||
## [[Hypoxic encephalopathy]]<ref>Wickramasinghe LS, Chazan BI, Mandal AR, Baylis PH, Russell I: Cranial diabetes insipidus after upper gastrointestinal hemorrhage. British medical journal (Clinical research ed) 1988, 296(6627):969.</ref> | |||
## Infiltrative disorders ( [[histiocytosis X]], [[sarcoidosis]], [[granulomatosis with polyangiitis]])<ref>Dunger DB, Broadbent V, Yeoman E, Seckl JR, Lightman SL, Grant DB, Pritchard J: The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. The New England journal of medicine 1989, 321(17):1157-1162.</ref><ref>Garovic VD, Clarke BL, Chilson TS, Specks U: Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. American journal of kidney diseases : the official journal of the National Kidney Foundation 2001, 37(1):E5.</ref> | |||
## Post-supraventricular tachycardia<ref>Canepa-Anson R, Williams M, Marshall J, Mitsuoka T, Lightman S, Sutton R: Mechanism of polyuria and natriuresis in atrioventricular nodal tachycardia. British medical journal (Clinical research ed) 1984, 289(6449):866-868.</ref><ref>Fujii T, Kojima S, Imanishi M, Ohe T, Omae T: Different mechanisms of polyuria and natriuresis associated with paroxysmal supraventricular tachycardia. The American journal of cardiology 1991, 68(4):343-348.</ref> | |||
## [[Anorexia nervosa]]<ref>Gold PW, Kaye W, Robertson GL, Ebert M: Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa. The New England journal of medicine 1983, 308(19):1117-1123.</ref> | |||
# '''[[Nephrogenic diabetes inspidous]]''' (NDI) | |||
## Hereditary NDI<ref>van Lieburg AF, Knoers NV, Monnens LA: Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. Journal of the American Society of Nephrology : JASN 1999, 10(9):1958-1964.</ref><ref>van Lieburg AF, Knoers NV, Monnens LA: Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. Journal of the American Society of Nephrology : JASN 1999, 10(9):1958-1964.</ref> | |||
## [[Lithium]]<ref>Grunfeld JP, Rossier BC: Lithium nephrotoxicity revisited. Nature reviews Nephrology 2009, 5(5):270-276.</ref> | |||
## [[Hypercalcemia]]<ref>Berl T: The cAMP system in vasopressin-sensitive nephron segments of the vitamin D-treated rat. Kidney international 1987, 31(5):1065-1071.</ref><ref>Peterson LN, McKay AJ, Borzecki JS: Endogenous prostaglandin E2 mediates inhibition of rat thick ascending limb Cl reabsorption in chronic hypercalcemia. The Journal of clinical investigation 1993, 91(6):2399-2407.</ref> | |||
## [[Hypokalemia]]<ref>Marples D, Frokiaer J, Dorup J, Knepper MA, Nielsen S: Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. The Journal of clinical investigation 1996, 97(8):1960-1968.</ref><ref>Jung JY, Madsen KM, Han KH, Yang CW, Knepper MA, Sands JM, Kim J: Expression of urea transporters in potassium-depleted mouse kidney. American journal of physiology Renal physiology 2003, 285(6):F1210-1224.</ref> | |||
## Renal disease: | |||
### Bilateral [[urinary tract obstruction]]<ref>Frokiaer J, Marples D, Knepper MA, Nielsen S: Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney. The American journal of physiology 1996, 270(4 Pt 2):F657-668.</ref> | |||
### [[Medullary cystic kidney disease]]<ref name="cyst">Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW: The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney international 1989, 35(2):675-680.</ref> | |||
### [[Amyloidosis]]<ref>Carone FA, Epstein FH: Nephrogenic diabetes insipidus caused by amyloid disease. Evidence in man of the role of the collecting ducts in concentrating urine. The American journal of medicine 1960, 29:539-544.</ref> | |||
### [[Sjogren's syndrome]]<ref>Shearn MA, Tu WH: NEPHROGENIC DIABETIC INSIPIDUS AND OTHER DEFECTS OF RENAL TUBULAR FUNCTION IN SJOERGREN'S SYNDROME. The American journal of medicine 1965, 39:312-318.</ref> | |||
### [[Autosomal dominant polycystic kidney disease]]<ref name="cyst">Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW: The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney international 1989, 35(2):675-680.</ref> | |||
### [[Sickle cell disease]]<ref>Scolari F, Caridi G, Rampoldi L, Tardanico R, Izzi C, Pirulli D, Amoroso A, Casari G, Ghiggeri GM: Uromodulin storage diseases: clinical aspects and mechanisms. American journal of kidney diseases : the official journal of the National Kidney Foundation 2004, 44(6):987-999.</ref> | |||
## Medications: | |||
### [[Cidofovir]]<ref>Schliefer K, Rockstroh JK, Spengler U, Sauerbruch T: Nephrogenic diabetes insipidus in a patient taking cidofovir. Lancet (London, England) 1997, 350(9075):413-414.</ref> | |||
### [[Foscarnet]]<ref>Navarro JF, Quereda C, Quereda C, Gallego N, Antela A, Mora C, Ortuno J: Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. American journal of kidney diseases : the official journal of the National Kidney Foundation 1996, 27(3):431-434.</ref> | |||
### [[Amphotericin B]] | |||
### [[Demeclocycline]] | |||
### [[Ifosfamide]] | |||
### [[Ofloxacin]] | |||
### [[Orlistat]] | |||
### [[Didanosine]]<ref>D'Ythurbide G, Goujard C, Mechai F, Blanc A, Charpentier B, Snanoudj R: Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2007, 22(12):3656-3659.</ref> | |||
### V2 receptor antagonists<ref>Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. The New England journal of medicine 2006, 355(20):2099-2112.</ref> | |||
## Gestational diabetes insipidus<ref>Brewster UC, Hayslett JP: Diabetes insipidus in the third trimester of pregnancy. Obstetrics and gynecology 2005, 105(5 Pt 2):1173-1176.</ref><ref>Aleksandrov N, Audibert F, Bedard MJ, Mahone M, Goffinet F, Kadoch IJ: Gestational diabetes insipidus: a review of an underdiagnosed condition. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2010, 32(3):225-231.</ref> | |||
## [[Craniopharyngioma]] surgery<ref>Ghirardello S, Hopper N, Albanese A, Maghnie M: Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. Journal of pediatric endocrinology & metabolism : JPEM 2006, 19 Suppl 1:413-421.</ref> | |||
## Bardet-biedl syndrome<ref>Anadoliiska A, Roussinov D: Clinical aspects of renal involvement in Bardet-Biedl syndrome. International urology and nephrology 1993, 25(5):509-514.</ref> | |||
## [[Bartter syndrome]]<ref>Jeck N, Schlingmann KP, Reinalter SC, Komhoff M, Peters M, Waldegger S, Seyberth HW: Salt handling in the distal nephron: lessons learned from inherited human disorders. American journal of physiology Regulatory, integrative and comparative physiology 2005, 288(4):R782-795.</ref> | |||
## [[Cystinosis]]<ref>Knoepfelmacher M1, Rocha R, Salgado LR, et al. [Nephropathic cystinosis: report of 2 cases and review of the literature]. Rev Assoc Med Bras 1994; 40:43.</ref> | |||
# '''Primary Polydipsia''' | |||
# '''[[Osmotic diuresis]]''': [[Diabetes mellitus]] | |||
''' | ===Causes by Organ System=== | ||
{| style="width:80%; height:100px" border="1" | |||
| style="width:25%" bgcolor="LightSteelBlue" ; border="1" |'''Cardiovascular''' | |||
| style="width:75%" bgcolor="Beige" ; border="1" | [[Cardiorespiratory disease]], [[Circulation]], [[Congestive heart failure]], [[Paroxysmal tachycardia]] | |||
|- | |||
| bgcolor="LightSteelBlue" | '''Chemical/Poisoning''' | |||
| bgcolor="Beige" | 3,3-dichlorobenzidine, [[Caffeine]] poisoning, [[Foscarnet sodium]], [[Frusemide]], Juniper tar poisoning, Oak poisoning, [[Silicon dioxide]], Sodium ferrocyanide, [[Sorbitol]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Dental''' | |||
| bgcolor="Beige" | No underlying causes | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Dermatologic''' | |||
| bgcolor="Beige" | No underlying causes | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Drug Side Effect''' | |||
| bgcolor="Beige" | [[Amitraz ]] , BCG vaccine, [[Bendrofluazide]], [[Bumetanide]], [[Canagliflozin]], [[Conivaptan]], [[Dapagliflozin]], Diuretic therapy, [[Empagliflozin]], [[Goserelin]], [[Hydrochlorothiazide]], [[Isosorbide]], [[Lithium]], [[Mannitol]], [[Nabilone]], [[Phendimetrazine]], [[Probenecid]], [[Tiagabine]], [[Tolvaptan]], [[corticosteroid]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Ear Nose Throat''' | |||
| bgcolor="Beige" | [[Sicca syndrome]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Endocrine''' | |||
| bgcolor="Beige" | [[Adrenal adenoma]], [[Adrenal cancer]], Adrenal cortex neoplasms, [[Adrenal gland hyperfunction]], [[Aldosteronism]], [[Conn's disease]], [[Cushing syndrome]], [[Cystinosis]], [[DKA]], Ectopic [[ACTH]] syndrome, Electrolyte abnormality, Familial hypopituitarism, [[Fanconi syndrome]], [[Froelich's syndrome]], Hair-an syndrome, [[Hormonal]], [[Hyperadrenalism]], [[Hypercalcemia]], [[Hypercalcuria]], [[Hyperglycemia]], [[Hyperosmolar hyperglycemic nonketotic syndrome]], [[Hyperparathyroidism]], [[Hyperthyroidism]], [[Hypokalemia]], [[Hypokalemic periodic paralysis]], [[Hypopituitarism]], [[Hypothalamic dysfunction]], Intermediate cystinosis, [[Multiple endocrine neoplasia]], [[Panhypopituitarism]], [[Parathyroid cancer]], [[Pheochromocytoma]], [[Pituitary tumors]], [[Postural orthostatic tachycardia syndrome]], [[Primary hyperaldosteronism]], [[Syndrome of inappropriate antidiuretic hormone]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Environmental''' | |||
| bgcolor="Beige" | [[Postobstructive uropathy]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Gastroenterologic''' | |||
| bgcolor="Beige" | [[Gestational diabetes]], Rib tumor, [[Wandering spleen]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Genetic''' | |||
| bgcolor="Beige" | [[Aceruloplasminemia]], Amelogenesis imperfeca, [[Apparent mineralocorticoid excess]], [[Bartter syndrome]], Boichis syndrome, Conn's disease, Dend syndrome, East syndrome, [[Gitelman syndrome]], Hair-an syndrome, Hereditary primary fanconi disease, Machado-joseph disease, Senior-loken syndrome, [[Wolfram's disease]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Hematologic''' | |||
| bgcolor="Beige" | [[Diabetes insipidus ]] , [[Diabetes mellitus]], [[Excessive riboflavin]], [[Excessive vitamin d]], [[Hemochromatosis ]] , [[Hhns]], [[Hypercalcemia]], [[Hypercalcuria ]] , [[Hyperglycemia ]] , [[Hyperosmolar hyperglycemic nonketotic syndrome ]] , [[Hypervitaminosis a]], [[Hypervitaminosis d]], [[Hypokalemia]], [[Hypokalemic periodic paralysis ]] , [[Langerhans cell histiocytosis ]] , [[Leukemia]], [[Neurosarcoidosis ]] , [[Proximal renal tubular acidosis ]] , [[Resolving hematoma]], [[Sickle-cell anemia]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Iatrogenic''' | |||
| bgcolor="Beige" | [[Bcg vaccine]], [[Chemotherapy-induced cystitis]], [[Diuretic therapy]], [[Pelvic lipomatosis ]] , [[Radiation cystitis]], [[Radiographic contrast media]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Infectious Disease''' | |||
| bgcolor="Beige" | [[Gonococcal urethritis ]] , [[Serratia urinary tract infection ]] , [[Streptococcal group b invasive disease ]] , [[Urinary tract infection]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Musculoskeletal/Orthopedic''' | |||
| bgcolor="Beige" | [[Back tumor ]] , [[Hip cancer ]] , [[Pyelonephritis]], [[Secondary bone cancer ]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Neurologic''' | |||
| bgcolor="Beige" | [[Adrenocortical carcinoma]], [[Anorexia nervosa]], [[Cerebral salt-wasting syndrome]], [[Diencephalic syndrome]], [[Migraine]], [[Neurologic damage]], [[Neurosarcoidosis]], Olivopontocerebellar atrophy type 3, [[Postural orthostatic tachycardia syndrome]], [[Psychogenic polydipsia]], [[Seizures]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Nutritional/Metabolic''' | |||
| bgcolor="Beige" | [[Aceruloplasminemia]], Dend syndrome, [[Diabetes insipidus]], [[Diabetes mellitus]], [[Diabetic nephropathy]], Excessive [[riboflavin]], Excessive [[vitamin d]], [[Gestational diabetes]], Hhns, Hypervitaminosis a, Hypervitaminosis d, [[Nephrogenic diabetes insipidus]], [Renal tubular transport disorders]], [[Renal tubulopathy ]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Obstetric/Gynecologic''' | |||
| bgcolor="Beige" | [[Ovarian cysts]], [[Premenstrual syndrome]], [[Vagina cancer]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Oncologic''' | |||
| bgcolor="Beige" | [[Adrenal adenoma]], [[Adrenal cancer]], Adrenal cortex neoplasms, [[Adrenal incidentaloma]], [[Adrenocortical carcinoma]], Back tumor, [[Bladder cancer]], [[Chemotherapy-induced cystitis]], Conn-louis carcinoma, [[Conn's adenoma]], Ectopic [[ACTH]]syndrome, Erdheim-chester disease, Hip cancer, [[Leukemia]], [[Parathyroid cancer]], [[Pituitary tumors]], [[Prostate cancer]], Prostate conditions, [[Renal cell cancer]], Rib tumor, Secondary bone cancer, [[Urethral cancer]], [[Uterine leiomyoma]], Vagina cancer | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Ophthalmologic''' | |||
| bgcolor="Beige" | No underlying causes | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Overdose/Toxicity''' | |||
| bgcolor="Beige" | No underlying causes | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Psychiatric''' | |||
| bgcolor="Beige" | [[Anorexia nervosa ]] , [[Combat stress reaction ]] , [[Generalized anxiety disorder]], [[Seizures]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Pulmonary''' | |||
| bgcolor="Beige" | [[Cardiorespiratory disease]], [[East syndrome ]] , [[Heerfordt syndrome ]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Renal/Electrolyte''' | |||
| bgcolor="Beige" | [[Acid-base imbalance]], [[Acute tubular necrosis]], [[Aldosteronism]], [[Alsing syndrome ]] , [[Altitude diuresis]], [[Apparent mineralocorticoid excess ]] , [[Bartter syndrome ]] , [[Boichis syndrome ]] , [[Cerebral salt-wasting syndrome]], [[Chronic glomerulonephritis]], [[Chronic interstitial nephritis]], [[Chronic kidney disease ]] , [[Chronic renal failure]], [[Chronic wasting disease ]] , [[Cystitis ]] , [[Danubian endemic familial nephropathy]], [[Diabetic nephropathy ]] , [[Early chronic pyelonephritis]], [[Electrolyte abnormality ]] , [[Eosinophilic cystitis]], [[Gitelman syndrome ]] , [[Glomerulonephritis ]] , [[Interstitial cystitis]], [[Juvenile nephronophthisis ]] , [[Medullary cystic kidney disease ]] , [[Megalocytic interstitial nephritis ]] , [[Membranoproliferative glomerulonephritis ]] , [[Nephrocalcinosis ]] , [[Nephrogenic diabetes insipidus ]] , [[Nephrolithiasis ]] , [[Nephronophthisis]], [[Nephropathic cystinosis ]] , [[Oligomeganephronic renal hypoplasia ]] , [[Osmotic diuresis]], [[Polycystic kidney disease ]] , [[Polydipsia]], [[Primary tubular proximal acidosis ]] , [[Proximal renal tubular acidosis ]] , [[Proximal tubulopathy]], [[Psychogenic polydipsia]], [[Pyelonephritis]], [[Radiation cystitis]], [[Reflux nephropathy ]] , [[Renal cell cancer ]] , [[Renal failure]], [[Renal tubular acidosis]], [[Renal tubular transport disorders]], [[Renal tubulopathy ]] , [[Toni-fanconi syndrome type 1 ]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Rheumatology/Immunology/Allergy''' | |||
| bgcolor="Beige" | [[Heerfordt syndrome ]] , [[Neurosarcoidosis ]] , [[Reiter’s syndrome ]] , [[Uterine fibroids ]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Sexual''' | |||
| bgcolor="Beige" | No underlying causes | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Trauma''' | |||
| bgcolor="Beige" | No underlying causes | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Urologic''' | |||
| bgcolor="Beige" | [[Benign prostatic hyperplasia]], [[Bladder cancer ]] , Bladder compression, Bladder conditions, [[Bladder diverticulum]], [[Enlarged prostate ]] , Noctural polyuria syndrome, [[Overactive bladder]], Pathological water intake, ostobstructive uropathy, [[Prostate cancer|rostate cancer]], rostate conditions, Sassoon hospital syndrome, Serratia [[urinary tract infection]] [[Urethral cancer |rethral cancer]] , [[Urethritis ]] , rinary outflow obstruction, [[Urinary stones ]] [[Urinary tract infection]], [[Uterine fibroids |Uterine fibroids,]] [[Uterine leiomyoma ]] | |||
|- | |||
|- bgcolor="LightSteelBlue" | |||
| '''Miscellaneous''' | |||
| bgcolor="Beige" | No underlying causes | |||
|- | |||
|} | |||
==Causes== | ===Causes in Alphabetical Order=== | ||
<div style="-moz-column-count:3; column-count:3;"> | |||
*3,3-dichlorobenzidine | |||
*[[Aceruloplasminemia ]] | |||
*[[Acid-base imbalance]] | |||
*[[Acute tubular necrosis]] | |||
*[[Adrenal adenoma]] | |||
*[[Adrenal cancer]] | |||
*Adrenal cortex neoplasms | |||
*[[Adrenal gland hyperfunction ]] | |||
*[[Adrenal incidentaloma ]] | |||
*[[Adrenocortical carcinoma ]] | |||
*[[Aldosteronism]] | |||
*Alsing syndrome | |||
*Altitude diuresis | |||
*Amelogenesis imperfeca | |||
*[[Amitraz ]] | |||
*[[Anorexia nervosa ]] | |||
*[[Apparent mineralocorticoid excess ]] | |||
*Back tumor | |||
*[[Bartter syndrome ]] | |||
*[[BCG]] vaccine | |||
*[[Bendrofluazide]] | |||
*[[Benign prostatic hyperplasia]] | |||
*[[Bladder cancer]] | |||
*Bladder compression | |||
*[[Bladder diverticulum]] | |||
*Boichis syndrome | |||
*[[Bumetanide]] | |||
*[[Caffeine poisoning]] | |||
*[[Canagliflozin]] | |||
*Cardiorespiratory disease | |||
*[[Cerebral salt-wasting syndrome]] | |||
*Chemotherapy-induced cystitis | |||
*[[Chronic glomerulonephritis]] | |||
*[[Chronic interstitial nephritis]] | |||
*[[Chronic kidney disease ]] | |||
*[[Chronic renal failure]] | |||
*[[Chronic wasting disease ]] | |||
*[[Combat stress reaction ]] | |||
*[[Congestive heart failure ]] | |||
*[[Conivaptan]] | |||
*Conn-louis carcinoma | |||
*Conn's adenoma | |||
*[[Conn's syndrome ]] | |||
*[[Cushing syndrome]] | |||
*[[Cushing's syndrome]] | |||
*[[Cystinosis ]] | |||
*[[Cystitis ]] | |||
*[[Danubian endemic familial nephropathy]] | |||
*[[Dapagliflozin]] | |||
*Dend syndrome | |||
*[[Diabetes insipidus]] | |||
*[[Diabetes mellitus]] | |||
*[[Diabetic nephropathy ]] | |||
*[[Diencephalic syndrome ]] | |||
*Diuretic therapY | |||
*[[DKA]] | |||
*Early chronic pyelonephritis | |||
*East syndrome | |||
*Ectopic [[ACTH]] syndrome | |||
*Electrolyte abnormality | |||
*[[Empagliflozin]] | |||
*Eosinophilic cystitis | |||
*Erdheim-chester syndrome | |||
*Excessive [[riboflavin]] | |||
*Excessive [[vitamin d]] | |||
*Familial hypopituitarism | |||
*[[Fanconi syndrome ]] | |||
*[[Foscarnet sodium]] | |||
*Froelich's syndrome | |||
*[[Frusemide]] | |||
*[[Generalized anxiety disorder]] | |||
*[[Gestational diabetes]] | |||
*[[Gitelman syndrome ]] | |||
*[[Glomerulonephritis ]] | |||
*Gonococcal urethritis | |||
*[[Goserelin]] | |||
*Hair-an syndrome | |||
*[[Heerfordt syndrome ]] | |||
*[[Hemochromatosis ]] | |||
*Hereditary primary fanconi disease | |||
*Hhns | |||
*Hip cancer | |||
*[[Hormonal]] | |||
*[[Hydrochlorothiazide]] | |||
*[[Hyperadrenalism ]] | |||
*[[Hypercalcemia]] | |||
*[[Hypercalcuria ]] | |||
*[[Hyperglycemia ]] | |||
*[[Hyperosmolar hyperglycemic nonketotic syndrome ]] | |||
*[[Hyperosmolarity ]] | |||
*[[Hyperparathyroidism ]] | |||
*[[Hyperthyroidism]] | |||
*Hypervitaminosis a | |||
*Hypervitaminosis d | |||
*[[Hypokalemia ]] | |||
*[[Hypokalemic periodic paralysis ]] | |||
*[[Hypopituitarism]] | |||
*[[Hypothalamic dysfunction ]] | |||
*Intermediate cystinosis | |||
*[[Interstitial cystitis]] | |||
*[[Isosorbide]] | |||
*Juniper tar poisoning | |||
*Juvenile nephronophthisis | |||
*[[Langerhans cell histiocytosis ]] | |||
*[[Leukemia]] | |||
*[[Lithium]] | |||
*Machado-joseph disease | |||
*[[Mannitol]] | |||
*[[Medullary cystic kidney disease ]] | |||
*Megalocytic interstitial nephritis | |||
*[[Membranoproliferative glomerulonephritis ]] | |||
*[[Migraine]] | |||
*[[Multiple endocrine neoplasia ]] | |||
*[[Nabilone]] | |||
*[[Nephrocalcinosis ]] | |||
*[[Nephrogenic diabetes insipidus ]] | |||
*[[Nephrolithiasis ]] | |||
*[[Nephronophthisis]] | |||
*Nephronophthisis type 1 | |||
*[[Nephropathic cystinosis ]] | |||
*Neurologic damage | |||
*[[Neurosarcoidosis ]] | |||
*Noctural polyuria syndrome | |||
*Oak poisoning | |||
*Oligomeganephronic renal hypoplasia | |||
*Olivopontocerebellar atrophy type 3 | |||
*[[Osmotic diuresis]] | |||
*[[Ovarian cysts ]] | |||
*[[Overactive bladder]] | |||
*[[Panhypopituitarism ]] | |||
*[[Parathyroid cancer]] | |||
*[[Paroxysmal tachycardia]] | |||
*Pathological water intake | |||
*[[Pelvic lipomatosis ]] | |||
*[[Phendimetrazine]] | |||
*[[Pheochromocytoma]] | |||
*[[Pituitary tumors]] | |||
*[[Polycystic kidney disease ]] | |||
*[[Polydipsia]] | |||
*Postobstructive uropathy | |||
*[[Postural orthostatic tachycardia syndrome]] | |||
*[[Premenstrual syndrome ]] | |||
*[[Primary hyperaldosteronism ]] | |||
*Primary tubular proximal acidosis | |||
*[[Probenecid]] | |||
*[[Prostate cancer]] | |||
*[[Proximal renal tubular acidosis ]] | |||
*Proximal tubulopathy | |||
*[[Psychogenic polydipsia]] | |||
*[[Pyelonephritis]] | |||
*Radiation cystitis | |||
*Radiographic contrast media | |||
*[[Reflux nephropathy ]] | |||
*[[Reiter’s syndrome ]] | |||
*[[Renal cell cancer ]] | |||
*[[Renal failure]] | |||
*[[Renal tubular acidosis]] | |||
*Renal tubular transport disorders | |||
*Resolving hematoma | |||
*Rib tumor | |||
*Sassoon hospital syndrome | |||
*Secondary bone cancer | |||
*[[Seizures]] | |||
*Senior-loken syndrome | |||
*Serratia [[urinary tract infection]] | |||
*[[Sicca syndrome]] | |||
*[[Sickle-cell anemia]] | |||
*[[Silicon dioxide]] | |||
*Sodium ferrocyanide | |||
*[[Sorbitol]] | |||
*Streptococcal group b invasive disease | |||
*[[Syndrome of inappropriate antidiuretic hormone]] | |||
*[[Tiagabine]] | |||
*[[Tolvaptan]] | |||
*Toni-fanconi syndrome type 1 | |||
*[[Urethral cancer ]] | |||
*[[Urethritis ]] | |||
*Urinary outflow obstruction | |||
*[[Urinary stones ]] | |||
*[[Urinary tract infection]] | |||
*[[Uterine fibroids ]] | |||
*[[Uterine leiomyoma ]] | |||
*Vagina cancer | |||
*[[Wandering spleen ]] | |||
*[[Wolfram's disease ]] | |||
</div> | |||
==Differential Diagnosis of Polyuria== | |||
{{familytree/start |summary=polyuria diagnosis Algorithm.}} | |||
{{familytree | | | | | | | | A01 |A01='''Polyuria'''<br> ❑ 24-hour urine volume >'''3'''L <br> ❑ 24-hour urine volume >50 ml/kg}} | |||
{{familytree | | | | |,|-|-|-|^|-|-|-|-|.| | | }} | |||
{{familytree | | | B01 | | | | | | | | B02 | | |B01='''Urine Osmolality >300'''mosmol|B02='''Urine Osmolality <300<ref>Robertson GL: Diabetes insipidus. Endocrinol Metab Clin North Am 24:549–572, 1995.</ref>'''mosmol}} | |||
{{familytree | | | |!| | | | | | | | | |!| }} | |||
{{familytree | | | C01 | | | | | | | | |!| |C01='''Solute diuresis'''<br> ❑ [[Glucose]] <br> ❑ [[Mannitol]] <br> ❑ [[Contrast media]] <br> ❑ [[High protein intake]] <br> ❑ [[Diuretics]] <br> ❑ [[Medullary cystic disease]] <br> ❑ [[Resolving ATN]] <br> ❑ [[Resolving obstruction]] }} | |||
{{familytree | | | | | | | | | | | | | |!| }} | |||
{{familytree | | | | | | | | | | | | | D03 |D03='''Water diuresis'''<br> ❑ [[Primary polydipsia]] <br> ❑ [[Diabetes inspidous]]}} | |||
{{familytree | | | | | | | | | | | | | |!| | }} | |||
{{familytree | | | | | | | | | | | | | E02 | | |E02=Water restriction test '''OR''' administration of hypertonic saline 0.05 mL/kg/min for 2 h|}} | |||
{{familytree | | | | | | | | | | | | | |!| | | }} | |||
{{familytree | | | | | | | | | | | | | F01 | | | |F01='''Water restriction test''' | |||
<br> ❑ Overnight fluid restriction should be '''avoided''' <br> ❑ Recommend the patient to stop drinking 2-3 hours before coming to clinic <br> ❑ Meaure urine volume every hour <br> ❑ Measure urine osmolality every hour <br> ❑ Measure plasma sodium concentration every 2 hours <br> ❑ Measure plasma osmolality every 2 hours |F02=F02}} | |||
{{familytree | | | | | | | | | | | | | |!| }} | |||
{{familytree | | | | | | | | | | | | | G01 |G01='''Test endpoints in adults:''' <br> ❑ Urine osmolality reaches normal value (above 600 mosmol/kg)[means that ADH release and effect are intact] <br> ❑ The urine osmolality is stable for 2 or 3 successive hourly measurements despite a rising plasma osmolality <br> ❑ Plasma osmolality >295-300 mosmol/kg <br> ❑ Plasma sodium is 145 or higher |}} | |||
{{familytree | | | | | | | | | | | | | |!| | | }} | |||
{{familytree | | | | | | | | | | | | | H01 |H01=In the last 3 settings '''[[desmopressin]] 10mcg intranasal''', or 4mcg SC/IV is administered <br> ❑ Measure urine volume and urine osmolality every 30 minutes over the next two hours|}} | |||
{{familytree | | | | | | | | | |,|-|-|-|+|-|-|-|.|}} | |||
{{familytree | | | | | | | | |I01 | |I02 | | |I03|I01=>100% rise in urine osmolality|I02=15-50% rise in urine osmolality after administration of exogenous [[desmopressin]]|I03=<15% rise in urine osmolality}} | |||
{{familytree | | | | | | | | | |!| | | |!| | | |!|}} | |||
{{familytree | | | | | | | | |J01 | |J02 | | |J03|J01='''Complete central diabetes inspidous'''<ref>Zerbe RL, Robertson GL: A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. The New England journal of medicine 1981, 305(26):1539-1546.</ref>|J02='''Partial central DI''' or '''partial nephrogenic DI'''<ref>Miller M, Dalakos T, Moses AM, Fellerman H, Streeten DH: Recognition of partial defects in antidiuretic hormone secretion. Annals of internal medicine 1970, 73(5):721-729.</ref>|J03='''complete nephrogenic DI''' or [['''primary polydipsia''']]|}} | |||
{{familytree | | | | | | | | | | | | | |!| }} | |||
{{familytree | | | | | | | | | | | | | K01 |K01=Check plasma and urine [[ADH]]<ref>Diederich S, Eckmanns T, Exner P, Al-Saadi N, Bahr V, Oelkers W: Differential diagnosis of polyuric/polydipsic syndromes with the aid of urinary vasopressin measurement in adults. Clinical endocrinology 2001, 54(5):665-671.</ref>and [[copeptin]] prior to administration of exogenous ADH <br> ❑ Increase in plasma/urine [[ADH]] in response to rising plasma osmolality '''excludes''' [[central DI]] <br> ❑ Appropriate elevation in [[urine osmolality]] as [[ADH]] secretion is increased '''excludes''' nephrogenic DI <br> ❑ '''[[Copeptin]] > 21.4''' picomol/L differentiates Nephrogenic DI from other etiologies with 100% sensivity and specifity<ref> Timper K, Fenske W, Kuhn F, Frech N, Arici B, Rutishauser J, Kopp P, Allolio B, Stettler C, Muller B et al: Diagnostic Accuracy of Copeptin in the Differential Diagnosis of the Polyuria-polydipsia Syndrome: A Prospective Multicenter Study. The Journal of clinical endocrinology and metabolism 2015, 100(6):2268-2274.</ref>|}} | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
{| class="wikitable" | |||
! colspan="15" style="background:#4479BA; color: #FFFFFF;" |POLYURIA<ref name="BhasinVelez2016">{{cite journal|last1=Bhasin|first1=Bhavna|last2=Velez|first2=Juan Carlos Q.|title=Evaluation of Polyuria: The Roles of Solute Loading and Water Diuresis|journal=American Journal of Kidney Diseases|volume=67|issue=3|year=2016|pages=507–511|issn=02726386|doi=10.1053/j.ajkd.2015.10.021}}</ref> | |||
|- | |||
! colspan="2" rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Mechanism | |||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Etiology | |||
! colspan="6" style="background:#4479BA; color: #FFFFFF;" |Clinical manifestations | |||
! colspan="5" style="background:#4479BA; color: #FFFFFF;" |Paraclinical findings | |||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Comments | |||
|- | |||
! colspan="6" style="background:#4479BA; color: #FFFFFF;" |Symptoms and signs | |||
! colspan="5" style="background:#4479BA; color: #FFFFFF;" |Lab findings/Urine exam | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |Dysuria | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |Nocturia | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |Hesitancy | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |Dribbling | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |Hematuria | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |Proteinuria | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |Serum osmolarity | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |S. ADH | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |Urine osmolarity | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |Water deprivation test | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" |ADH administration | |||
|- | |||
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Increased intake of fluid | |||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Psychogenic polydipsia]]<ref name="pmid6860053">{{cite journal| author=Mellinger RC, Zafar MS| title=Primary polydipsia. Syndrome of inappropriate thirst. | journal=Arch Intern Med | year= 1983 | volume= 143 | issue= 6 | pages= 1249-51 | pmid=6860053 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6860053 }}</ref> | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Low | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Improves urine osmolarity | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No improvement | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Increased thirst | |||
|- | |||
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Increased solute excretion | |||
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Osmotic causes | |||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Diabetes mellitus]]<ref name="pmid104991902">{{cite journal| author=Ahloulay M, Schmitt F, Déchaux M, Bankir L| title=Vasopressin and urinary concentrating activity in diabetes mellitus. | journal=Diabetes Metab | year= 1999 | volume= 25 | issue= 3 | pages= 213-22 | pmid=10499190 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10499190 }}</ref> | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Late stage | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |High in type 2 | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperosmolar hyperglycemic state]] | |||
|- | |||
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Salt loss | |||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Diuretics]]<ref name="pmid21468197">{{cite journal| author=Hwang KS, Kim GH| title=Thiazide-induced hyponatremia. | journal=Electrolyte Blood Press | year= 2010 | volume= 8 | issue= 1 | pages= 51-7 | pmid=21468197 | doi=10.5049/EBP.2010.8.1.51 | pmc=3041494 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21468197 }}</ref><ref name="Loffing2004">{{cite journal|last1=Loffing|first1=J.|title=Paradoxical Antidiuretic Effect of Thiazides in Diabetes Insipidus: Another Piece in the Puzzle|journal=Journal of the American Society of Nephrology|volume=15|issue=11|year=2004|pages=2948–2950|issn=1046-6673|doi=10.1097/01.ASN.0000146568.82353.04}}</ref> | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Raised | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal, increased with thiazides | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cerebral salt-wasting syndrome]]<ref name="pmid20066633">{{cite journal| author=Ozdemir H, Aycan Z, Degerliyurt A, Metin A| title=The treatment of cerebral salt wasting with fludrocortisone in a child with lissencephaly. | journal=Turk Neurosurg | year= 2010 | volume= 20 | issue= 1 | pages= 100-2 | pmid=20066633 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20066633 }}</ref> | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Low | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Improves urine osmolarity | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
|- | |||
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Impaired urinary concentration | |||
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Low ADH | |||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Central diabetes insipidus]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Increased | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Low | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Low | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No improvement | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Urine osmolarity improves | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Nephrogenic diabetes insipidus]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Increased | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Low | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No improvement | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No improvement | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
|- | |||
! rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Renal disease | |||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Renal tubular acidosis]]<ref name="pmid19721811">{{cite journal| author=Pereira PC, Miranda DM, Oliveira EA, Silva AC| title=Molecular pathophysiology of renal tubular acidosis. | journal=Curr Genomics | year= 2009 | volume= 10 | issue= 1 | pages= 51-9 | pmid=19721811 | doi=10.2174/138920209787581262 | pmc=2699831 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19721811 }}</ref><ref name="pmid29178965">{{cite journal| author=Ranawaka R, Dayasiri K, Gamage M| title=A child with distal (type 1) renal tubular acidosis presenting with progressive gross motor developmental regression and acute paralysis. | journal=BMC Res Notes | year= 2017 | volume= 10 | issue= 1 | pages= 618 | pmid=29178965 | doi=10.1186/s13104-017-2949-2 | pmc=5702097 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29178965 }}</ref><ref name="pmid3624481">{{cite journal |vauthors=Bichara M, Mercier O, Houillier P, Paillard M, Leviel F |title=Effects of antidiuretic hormone on urinary acidification and on tubular handling of bicarbonate in the rat |journal=J. Clin. Invest. |volume=80 |issue=3 |pages=621–30 |date=September 1987 |pmid=3624481 |pmc=442283 |doi=10.1172/JCI113114 |url=}}</ref><ref name="SharmanLow2008">{{cite journal|last1=Sharman|first1=Andrew|last2=Low|first2=James|title=Vasopressin and its role in critical care|journal=Continuing Education in Anaesthesia Critical Care & Pain|volume=8|issue=4|year=2008|pages=134–137|issn=17431816|doi=10.1093/bjaceaccp/mkn021}}</ref> | |||
" | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Increased | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Raised | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Increases acidification | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
|- | |||
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Miscellaneous | |||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Benign Prostatic Hyperplasia (BPH)]]<ref name="pmid16379182">{{cite journal| author=Yoong HF, Sundaram MB, Aida Z| title=Prevalence of nocturnal polyuria in patients with benign prostatic hyperplasia. | journal=Med J Malaysia | year= 2005 | volume= 60 | issue= 3 | pages= 294-6 | pmid=16379182 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16379182 }}</ref><ref name="pmid19468456">{{cite journal |vauthors=Jin MH, Moon du G |title=Practical management of nocturia in urology |journal=Indian J Urol |volume=24 |issue=3 |pages=289–94 |date=July 2008 |pmid=19468456 |pmc=2684373 |doi=10.4103/0970-1591.42607 |url=}}</ref> | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Improvement | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
|- | |||
|} | |||
==Pathophysiology== | |||
=== Central diabetes inspidus (CDI)=== | |||
* Results from a deficiency in production, and release of functional [[AVP]], hence respond to administration of exogenous [[AVP]].<ref>Christensen JH, Siggaard C, Rittig S: Autosomal dominant familial neurohypophyseal diabetes insipidus. APMIS Suppl (109):92–95, 2003.</ref><ref>Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 16:2836–2846, 2005.</ref> | |||
* [[CDI]] can be acquired or hereditary. ADH-producing cells' injury in [[hypothalamus]]/[[pituitary]] can be idiopathic, or due to trauma or infection. | |||
* Hereditary forms of familial CDI can occur secondary to 66 different mutations of the genes encoding AVP-neurophysin II precursor.<ref>Makaryus AN, McFarlane SI: Diabetes insipidus: diagnosis and | |||
treatment of a complex disease. Cleve Clin J Med 73:65–71, 2006.</ref> | |||
* | === Nephrogenic diabetes insipidus (NDI)=== | ||
* It results from an inappropriate renal response to AVP and usually reflects a functional defect in V2R or AQP2 protein.<ref>Bichet DG: Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol 28:245–251, 2008.</ref> | |||
* Administration of AVP, therefore is not sufficient to rectify the concentration defect. It is more commonly an acquired disease.<ref>Moeller HB, Rittig S, Fenton RA: Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev 34:278–301, 2013.</ref> | |||
* Over 225 different mutations in AVPR2 represent almost 90% of hereditary NDI cases. | |||
== | === Diabetes mellitus=== | ||
* Glucose-induced [[osmotic diuresis]] is the major etiology of polyuria in patients with [[hyperglycemia]].<ref>Spira A, Gowrishankar M, Halperin ML: Factors contributing to the degree of polyuria in a patient with poorly controlled diabetes mellitus. American journal of kidney diseases : the official journal of the National Kidney Foundation 1997, 30(6):829-835.</ref> | |||
In | ===Primary polydipsia=== | ||
* It is presumed that a central defect in thirst regulation has an important role in pathophysiology of [[polydipsia]]. | |||
* In some [[polydipsia]] patients for example, the osmotic threshold for thirst is reduced below the threshold for release of [[AVP]].<ref>Illowsky BP, Kirch DG: Polydipsia and hyponatremia in psychiatric patients. The American journal of psychiatry 1988, 145(6):675-683.</ref> | |||
* [[AVP]] is suppressed by fall in plasma osmolality(because of excessive water intake), and causes rapid excretion of the excess water and continued stimulation of thirst.<ref>Goldman MB, Luchins DJ, Robertson GL: Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. The New England journal of medicine 1988, 318(7):397-403.</ref> | |||
==Complications== | |||
* [[ | * Polyuria can result in [[dehydration]], [[hypernatremia]] and electrolyte abnormalities if the etiology is solute diuresis. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Urology]] | |||
[[Category:Symptoms]] | |||
[[Category:Signs and symptoms]] | |||
[[Category:Nephrology]] | |||
[[fr:Polyurie]] | [[fr:Polyurie]] | ||
[[pt:Poliúria]] | [[pt:Poliúria]] | ||
[[zh:多尿症]] | [[zh:多尿症]] | ||
[[pl:Wielomocz]] | [[pl:Wielomocz]] | ||
[[tr:Poliüri]] | [[tr:Poliüri]] | ||
Latest revision as of 04:19, 17 February 2021
Resident Survival Guide |
Template:Search infobox
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2] Luke Rusowicz-Orazem, B.S., Roshan Dinparasti Saleh M.D.
To view a comprehensive algorithm of common findings of urine composition and urine output, click here
Overview
Polyuria is the passage of a large volume of urine in a given period (>= 2.5L/24 hours in adult humans). It often appears with increased thirst (polydipsia). Various causes of polyuria include
Causes
- Central diabetes inispidus (CDI)
- Idiopathic CDI: the most common cause of CDI[1][2]
- Familial CDI[3]
- Wolfram syndrome ( DIDOMAD syndrome)[4]
- Congenital hypopituitarism[5]
- Septo-optic dysplasia[6]
- Surgery/trauma[7]
- Cancer (lung cancer, leukemia, lymphoma)[1]
- Hypoxic encephalopathy[8]
- Infiltrative disorders ( histiocytosis X, sarcoidosis, granulomatosis with polyangiitis)[9][10]
- Post-supraventricular tachycardia[11][12]
- Anorexia nervosa[13]
- Nephrogenic diabetes inspidous (NDI)
- Hereditary NDI[14][15]
- Lithium[16]
- Hypercalcemia[17][18]
- Hypokalemia[19][20]
- Renal disease:
- Medications:
- Cidofovir[26]
- Foscarnet[27]
- Amphotericin B
- Demeclocycline
- Ifosfamide
- Ofloxacin
- Orlistat
- Didanosine[28]
- V2 receptor antagonists[29]
- Gestational diabetes insipidus[30][31]
- Craniopharyngioma surgery[32]
- Bardet-biedl syndrome[33]
- Bartter syndrome[34]
- Cystinosis[35]
- Primary Polydipsia
- Osmotic diuresis: Diabetes mellitus
Causes by Organ System
Causes in Alphabetical Order
- 3,3-dichlorobenzidine
- Aceruloplasminemia
- Acid-base imbalance
- Acute tubular necrosis
- Adrenal adenoma
- Adrenal cancer
- Adrenal cortex neoplasms
- Adrenal gland hyperfunction
- Adrenal incidentaloma
- Adrenocortical carcinoma
- Aldosteronism
- Alsing syndrome
- Altitude diuresis
- Amelogenesis imperfeca
- Amitraz
- Anorexia nervosa
- Apparent mineralocorticoid excess
- Back tumor
- Bartter syndrome
- BCG vaccine
- Bendrofluazide
- Benign prostatic hyperplasia
- Bladder cancer
- Bladder compression
- Bladder diverticulum
- Boichis syndrome
- Bumetanide
- Caffeine poisoning
- Canagliflozin
- Cardiorespiratory disease
- Cerebral salt-wasting syndrome
- Chemotherapy-induced cystitis
- Chronic glomerulonephritis
- Chronic interstitial nephritis
- Chronic kidney disease
- Chronic renal failure
- Chronic wasting disease
- Combat stress reaction
- Congestive heart failure
- Conivaptan
- Conn-louis carcinoma
- Conn's adenoma
- Conn's syndrome
- Cushing syndrome
- Cushing's syndrome
- Cystinosis
- Cystitis
- Danubian endemic familial nephropathy
- Dapagliflozin
- Dend syndrome
- Diabetes insipidus
- Diabetes mellitus
- Diabetic nephropathy
- Diencephalic syndrome
- Diuretic therapY
- DKA
- Early chronic pyelonephritis
- East syndrome
- Ectopic ACTH syndrome
- Electrolyte abnormality
- Empagliflozin
- Eosinophilic cystitis
- Erdheim-chester syndrome
- Excessive riboflavin
- Excessive vitamin d
- Familial hypopituitarism
- Fanconi syndrome
- Foscarnet sodium
- Froelich's syndrome
- Frusemide
- Generalized anxiety disorder
- Gestational diabetes
- Gitelman syndrome
- Glomerulonephritis
- Gonococcal urethritis
- Goserelin
- Hair-an syndrome
- Heerfordt syndrome
- Hemochromatosis
- Hereditary primary fanconi disease
- Hhns
- Hip cancer
- Hormonal
- Hydrochlorothiazide
- Hyperadrenalism
- Hypercalcemia
- Hypercalcuria
- Hyperglycemia
- Hyperosmolar hyperglycemic nonketotic syndrome
- Hyperosmolarity
- Hyperparathyroidism
- Hyperthyroidism
- Hypervitaminosis a
- Hypervitaminosis d
- Hypokalemia
- Hypokalemic periodic paralysis
- Hypopituitarism
- Hypothalamic dysfunction
- Intermediate cystinosis
- Interstitial cystitis
- Isosorbide
- Juniper tar poisoning
- Juvenile nephronophthisis
- Langerhans cell histiocytosis
- Leukemia
- Lithium
- Machado-joseph disease
- Mannitol
- Medullary cystic kidney disease
- Megalocytic interstitial nephritis
- Membranoproliferative glomerulonephritis
- Migraine
- Multiple endocrine neoplasia
- Nabilone
- Nephrocalcinosis
- Nephrogenic diabetes insipidus
- Nephrolithiasis
- Nephronophthisis
- Nephronophthisis type 1
- Nephropathic cystinosis
- Neurologic damage
- Neurosarcoidosis
- Noctural polyuria syndrome
- Oak poisoning
- Oligomeganephronic renal hypoplasia
- Olivopontocerebellar atrophy type 3
- Osmotic diuresis
- Ovarian cysts
- Overactive bladder
- Panhypopituitarism
- Parathyroid cancer
- Paroxysmal tachycardia
- Pathological water intake
- Pelvic lipomatosis
- Phendimetrazine
- Pheochromocytoma
- Pituitary tumors
- Polycystic kidney disease
- Polydipsia
- Postobstructive uropathy
- Postural orthostatic tachycardia syndrome
- Premenstrual syndrome
- Primary hyperaldosteronism
- Primary tubular proximal acidosis
- Probenecid
- Prostate cancer
- Proximal renal tubular acidosis
- Proximal tubulopathy
- Psychogenic polydipsia
- Pyelonephritis
- Radiation cystitis
- Radiographic contrast media
- Reflux nephropathy
- Reiter’s syndrome
- Renal cell cancer
- Renal failure
- Renal tubular acidosis
- Renal tubular transport disorders
- Resolving hematoma
- Rib tumor
- Sassoon hospital syndrome
- Secondary bone cancer
- Seizures
- Senior-loken syndrome
- Serratia urinary tract infection
- Sicca syndrome
- Sickle-cell anemia
- Silicon dioxide
- Sodium ferrocyanide
- Sorbitol
- Streptococcal group b invasive disease
- Syndrome of inappropriate antidiuretic hormone
- Tiagabine
- Tolvaptan
- Toni-fanconi syndrome type 1
- Urethral cancer
- Urethritis
- Urinary outflow obstruction
- Urinary stones
- Urinary tract infection
- Uterine fibroids
- Uterine leiomyoma
- Vagina cancer
- Wandering spleen
- Wolfram's disease
Differential Diagnosis of Polyuria
Polyuria ❑ 24-hour urine volume >3L ❑ 24-hour urine volume >50 ml/kg | |||||||||||||||||||||||||||||||||||||||||
Urine Osmolality >300mosmol | Urine Osmolality <300[36]mosmol | ||||||||||||||||||||||||||||||||||||||||
Solute diuresis ❑ Glucose ❑ Mannitol ❑ Contrast media ❑ High protein intake ❑ Diuretics ❑ Medullary cystic disease ❑ Resolving ATN ❑ Resolving obstruction | |||||||||||||||||||||||||||||||||||||||||
Water diuresis ❑ Primary polydipsia ❑ Diabetes inspidous | |||||||||||||||||||||||||||||||||||||||||
Water restriction test OR administration of hypertonic saline 0.05 mL/kg/min for 2 h | |||||||||||||||||||||||||||||||||||||||||
Water restriction test
❑ Overnight fluid restriction should be avoided ❑ Recommend the patient to stop drinking 2-3 hours before coming to clinic ❑ Meaure urine volume every hour ❑ Measure urine osmolality every hour ❑ Measure plasma sodium concentration every 2 hours ❑ Measure plasma osmolality every 2 hours | |||||||||||||||||||||||||||||||||||||||||
Test endpoints in adults: ❑ Urine osmolality reaches normal value (above 600 mosmol/kg)[means that ADH release and effect are intact] ❑ The urine osmolality is stable for 2 or 3 successive hourly measurements despite a rising plasma osmolality ❑ Plasma osmolality >295-300 mosmol/kg ❑ Plasma sodium is 145 or higher | |||||||||||||||||||||||||||||||||||||||||
In the last 3 settings desmopressin 10mcg intranasal, or 4mcg SC/IV is administered ❑ Measure urine volume and urine osmolality every 30 minutes over the next two hours | |||||||||||||||||||||||||||||||||||||||||
>100% rise in urine osmolality | 15-50% rise in urine osmolality after administration of exogenous desmopressin | <15% rise in urine osmolality | |||||||||||||||||||||||||||||||||||||||
Complete central diabetes inspidous[37] | Partial central DI or partial nephrogenic DI[38] | complete nephrogenic DI or '''primary polydipsia''' | |||||||||||||||||||||||||||||||||||||||
Check plasma and urine ADH[39]and copeptin prior to administration of exogenous ADH ❑ Increase in plasma/urine ADH in response to rising plasma osmolality excludes central DI ❑ Appropriate elevation in urine osmolality as ADH secretion is increased excludes nephrogenic DI ❑ Copeptin > 21.4 picomol/L differentiates Nephrogenic DI from other etiologies with 100% sensivity and specifity[40] | |||||||||||||||||||||||||||||||||||||||||
POLYURIA[41] | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mechanism | Etiology | Clinical manifestations | Paraclinical findings | Comments | ||||||||||
Symptoms and signs | Lab findings/Urine exam | |||||||||||||
Dysuria | Nocturia | Hesitancy | Dribbling | Hematuria | Proteinuria | Serum osmolarity | S. ADH | Urine osmolarity | Water deprivation test | ADH administration | ||||
Increased intake of fluid | Psychogenic polydipsia[42] | – | – | – | – | – | – | Normal | Normal | Low | Improves urine osmolarity | No improvement | Increased thirst | |
Increased solute excretion | Osmotic causes | Diabetes mellitus[43] | – | ± | – | – | – | Late stage | High in type 2 | Normal | Normal | No effect | No effect | Hyperosmolar hyperglycemic state |
Salt loss | Diuretics[44][45] | – | + | – | + | – | ± | Normal | Raised | Normal, increased with thiazides | No effect | No effect | – | |
Cerebral salt-wasting syndrome[46] | – | – | – | – | – | – | Normal | Normal | Low | Improves urine osmolarity | No effect | – | ||
Impaired urinary concentration | Low ADH | Central diabetes insipidus | – | + | – | – | ± | ± | Increased | Low | Low | No improvement | Urine osmolarity improves | – |
Nephrogenic diabetes insipidus | – | + | – | – | ± | ± | Increased | Normal | Low | No improvement | No improvement | – | ||
Renal disease | Renal tubular acidosis[47][48][49][50] | ± | ± | – | – | ± | + | Increased | Raised | Normal | No effect | Increases acidification | – | |
Miscellaneous | Benign Prostatic Hyperplasia (BPH)[51][52] | + | + | + | + | ± | – | Normal | Normal | Normal | No effect | Improvement | – |
Pathophysiology
Central diabetes inspidus (CDI)
- Results from a deficiency in production, and release of functional AVP, hence respond to administration of exogenous AVP.[53][54]
- CDI can be acquired or hereditary. ADH-producing cells' injury in hypothalamus/pituitary can be idiopathic, or due to trauma or infection.
- Hereditary forms of familial CDI can occur secondary to 66 different mutations of the genes encoding AVP-neurophysin II precursor.[55]
Nephrogenic diabetes insipidus (NDI)
- It results from an inappropriate renal response to AVP and usually reflects a functional defect in V2R or AQP2 protein.[56]
- Administration of AVP, therefore is not sufficient to rectify the concentration defect. It is more commonly an acquired disease.[57]
- Over 225 different mutations in AVPR2 represent almost 90% of hereditary NDI cases.
Diabetes mellitus
- Glucose-induced osmotic diuresis is the major etiology of polyuria in patients with hyperglycemia.[58]
Primary polydipsia
- It is presumed that a central defect in thirst regulation has an important role in pathophysiology of polydipsia.
- In some polydipsia patients for example, the osmotic threshold for thirst is reduced below the threshold for release of AVP.[59]
- AVP is suppressed by fall in plasma osmolality(because of excessive water intake), and causes rapid excretion of the excess water and continued stimulation of thirst.[60]
Complications
- Polyuria can result in dehydration, hypernatremia and electrolyte abnormalities if the etiology is solute diuresis.
References
- ↑ 1.0 1.1 Kimmel DW, O'Neill BP: Systemic cancer presenting as diabetes insipidus. Clinical and radiographic features of 11 patients with a review of metastatic-induced diabetes insipidus. Cancer 1983, 52(12):2355-2358.
- ↑ Maghnie M, Cosi G, Genovese E, Manca-Bitti ML, Cohen A, Zecca S, Tinelli C, Gallucci M, Bernasconi S, Boscherini B et al: Central diabetes insipidus in children and young adults. The New England journal of medicine 2000, 343(14):998-1007.
- ↑ Christensen JH, Rittig S: Familial neurohypophyseal diabetes insipidus--an update. Seminars in nephrology 2006, 26(3):209-223.
- ↑ Bischoff AN, Reiersen AM, Buttlaire A, Al-Lozi A, Doty T, Marshall BA, Hershey T: Selective cognitive and psychiatric manifestations in Wolfram Syndrome. Orphanet journal of rare diseases 2015, 10:66.
- ↑ Lukezic M, Righini V, Di Natale B, De Angelis R, Norbiato G, Bevilacqua M, Chiumello G: Vasopressin and thirst in patients with posterior pituitary ectopia and hypopituitarism. Clinical endocrinology 2000, 53(1):77-83.
- ↑ Hoyt WF, Kaplan SL, Grumbach MM, Glaser JS: Septo-optic dysplasia and pituitary dwarfism. Lancet (London, England) 1970, 1(7652):893-894.
- ↑ Nemergut EC, Zuo Z, Jane JA, Jr., Laws ER, Jr.: Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. Journal of neurosurgery 2005, 103(3):448-454.
- ↑ Wickramasinghe LS, Chazan BI, Mandal AR, Baylis PH, Russell I: Cranial diabetes insipidus after upper gastrointestinal hemorrhage. British medical journal (Clinical research ed) 1988, 296(6627):969.
- ↑ Dunger DB, Broadbent V, Yeoman E, Seckl JR, Lightman SL, Grant DB, Pritchard J: The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. The New England journal of medicine 1989, 321(17):1157-1162.
- ↑ Garovic VD, Clarke BL, Chilson TS, Specks U: Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. American journal of kidney diseases : the official journal of the National Kidney Foundation 2001, 37(1):E5.
- ↑ Canepa-Anson R, Williams M, Marshall J, Mitsuoka T, Lightman S, Sutton R: Mechanism of polyuria and natriuresis in atrioventricular nodal tachycardia. British medical journal (Clinical research ed) 1984, 289(6449):866-868.
- ↑ Fujii T, Kojima S, Imanishi M, Ohe T, Omae T: Different mechanisms of polyuria and natriuresis associated with paroxysmal supraventricular tachycardia. The American journal of cardiology 1991, 68(4):343-348.
- ↑ Gold PW, Kaye W, Robertson GL, Ebert M: Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa. The New England journal of medicine 1983, 308(19):1117-1123.
- ↑ van Lieburg AF, Knoers NV, Monnens LA: Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. Journal of the American Society of Nephrology : JASN 1999, 10(9):1958-1964.
- ↑ van Lieburg AF, Knoers NV, Monnens LA: Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. Journal of the American Society of Nephrology : JASN 1999, 10(9):1958-1964.
- ↑ Grunfeld JP, Rossier BC: Lithium nephrotoxicity revisited. Nature reviews Nephrology 2009, 5(5):270-276.
- ↑ Berl T: The cAMP system in vasopressin-sensitive nephron segments of the vitamin D-treated rat. Kidney international 1987, 31(5):1065-1071.
- ↑ Peterson LN, McKay AJ, Borzecki JS: Endogenous prostaglandin E2 mediates inhibition of rat thick ascending limb Cl reabsorption in chronic hypercalcemia. The Journal of clinical investigation 1993, 91(6):2399-2407.
- ↑ Marples D, Frokiaer J, Dorup J, Knepper MA, Nielsen S: Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. The Journal of clinical investigation 1996, 97(8):1960-1968.
- ↑ Jung JY, Madsen KM, Han KH, Yang CW, Knepper MA, Sands JM, Kim J: Expression of urea transporters in potassium-depleted mouse kidney. American journal of physiology Renal physiology 2003, 285(6):F1210-1224.
- ↑ Frokiaer J, Marples D, Knepper MA, Nielsen S: Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney. The American journal of physiology 1996, 270(4 Pt 2):F657-668.
- ↑ 22.0 22.1 Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW: The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney international 1989, 35(2):675-680.
- ↑ Carone FA, Epstein FH: Nephrogenic diabetes insipidus caused by amyloid disease. Evidence in man of the role of the collecting ducts in concentrating urine. The American journal of medicine 1960, 29:539-544.
- ↑ Shearn MA, Tu WH: NEPHROGENIC DIABETIC INSIPIDUS AND OTHER DEFECTS OF RENAL TUBULAR FUNCTION IN SJOERGREN'S SYNDROME. The American journal of medicine 1965, 39:312-318.
- ↑ Scolari F, Caridi G, Rampoldi L, Tardanico R, Izzi C, Pirulli D, Amoroso A, Casari G, Ghiggeri GM: Uromodulin storage diseases: clinical aspects and mechanisms. American journal of kidney diseases : the official journal of the National Kidney Foundation 2004, 44(6):987-999.
- ↑ Schliefer K, Rockstroh JK, Spengler U, Sauerbruch T: Nephrogenic diabetes insipidus in a patient taking cidofovir. Lancet (London, England) 1997, 350(9075):413-414.
- ↑ Navarro JF, Quereda C, Quereda C, Gallego N, Antela A, Mora C, Ortuno J: Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. American journal of kidney diseases : the official journal of the National Kidney Foundation 1996, 27(3):431-434.
- ↑ D'Ythurbide G, Goujard C, Mechai F, Blanc A, Charpentier B, Snanoudj R: Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2007, 22(12):3656-3659.
- ↑ Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. The New England journal of medicine 2006, 355(20):2099-2112.
- ↑ Brewster UC, Hayslett JP: Diabetes insipidus in the third trimester of pregnancy. Obstetrics and gynecology 2005, 105(5 Pt 2):1173-1176.
- ↑ Aleksandrov N, Audibert F, Bedard MJ, Mahone M, Goffinet F, Kadoch IJ: Gestational diabetes insipidus: a review of an underdiagnosed condition. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2010, 32(3):225-231.
- ↑ Ghirardello S, Hopper N, Albanese A, Maghnie M: Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. Journal of pediatric endocrinology & metabolism : JPEM 2006, 19 Suppl 1:413-421.
- ↑ Anadoliiska A, Roussinov D: Clinical aspects of renal involvement in Bardet-Biedl syndrome. International urology and nephrology 1993, 25(5):509-514.
- ↑ Jeck N, Schlingmann KP, Reinalter SC, Komhoff M, Peters M, Waldegger S, Seyberth HW: Salt handling in the distal nephron: lessons learned from inherited human disorders. American journal of physiology Regulatory, integrative and comparative physiology 2005, 288(4):R782-795.
- ↑ Knoepfelmacher M1, Rocha R, Salgado LR, et al. [Nephropathic cystinosis: report of 2 cases and review of the literature]. Rev Assoc Med Bras 1994; 40:43.
- ↑ Robertson GL: Diabetes insipidus. Endocrinol Metab Clin North Am 24:549–572, 1995.
- ↑ Zerbe RL, Robertson GL: A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. The New England journal of medicine 1981, 305(26):1539-1546.
- ↑ Miller M, Dalakos T, Moses AM, Fellerman H, Streeten DH: Recognition of partial defects in antidiuretic hormone secretion. Annals of internal medicine 1970, 73(5):721-729.
- ↑ Diederich S, Eckmanns T, Exner P, Al-Saadi N, Bahr V, Oelkers W: Differential diagnosis of polyuric/polydipsic syndromes with the aid of urinary vasopressin measurement in adults. Clinical endocrinology 2001, 54(5):665-671.
- ↑ Timper K, Fenske W, Kuhn F, Frech N, Arici B, Rutishauser J, Kopp P, Allolio B, Stettler C, Muller B et al: Diagnostic Accuracy of Copeptin in the Differential Diagnosis of the Polyuria-polydipsia Syndrome: A Prospective Multicenter Study. The Journal of clinical endocrinology and metabolism 2015, 100(6):2268-2274.
- ↑ Bhasin, Bhavna; Velez, Juan Carlos Q. (2016). "Evaluation of Polyuria: The Roles of Solute Loading and Water Diuresis". American Journal of Kidney Diseases. 67 (3): 507–511. doi:10.1053/j.ajkd.2015.10.021. ISSN 0272-6386.
- ↑ Mellinger RC, Zafar MS (1983). "Primary polydipsia. Syndrome of inappropriate thirst". Arch Intern Med. 143 (6): 1249–51. PMID 6860053.
- ↑ Ahloulay M, Schmitt F, Déchaux M, Bankir L (1999). "Vasopressin and urinary concentrating activity in diabetes mellitus". Diabetes Metab. 25 (3): 213–22. PMID 10499190.
- ↑ Hwang KS, Kim GH (2010). "Thiazide-induced hyponatremia". Electrolyte Blood Press. 8 (1): 51–7. doi:10.5049/EBP.2010.8.1.51. PMC 3041494. PMID 21468197.
- ↑ Loffing, J. (2004). "Paradoxical Antidiuretic Effect of Thiazides in Diabetes Insipidus: Another Piece in the Puzzle". Journal of the American Society of Nephrology. 15 (11): 2948–2950. doi:10.1097/01.ASN.0000146568.82353.04. ISSN 1046-6673.
- ↑ Ozdemir H, Aycan Z, Degerliyurt A, Metin A (2010). "The treatment of cerebral salt wasting with fludrocortisone in a child with lissencephaly". Turk Neurosurg. 20 (1): 100–2. PMID 20066633.
- ↑ Pereira PC, Miranda DM, Oliveira EA, Silva AC (2009). "Molecular pathophysiology of renal tubular acidosis". Curr Genomics. 10 (1): 51–9. doi:10.2174/138920209787581262. PMC 2699831. PMID 19721811.
- ↑ Ranawaka R, Dayasiri K, Gamage M (2017). "A child with distal (type 1) renal tubular acidosis presenting with progressive gross motor developmental regression and acute paralysis". BMC Res Notes. 10 (1): 618. doi:10.1186/s13104-017-2949-2. PMC 5702097. PMID 29178965.
- ↑ Bichara M, Mercier O, Houillier P, Paillard M, Leviel F (September 1987). "Effects of antidiuretic hormone on urinary acidification and on tubular handling of bicarbonate in the rat". J. Clin. Invest. 80 (3): 621–30. doi:10.1172/JCI113114. PMC 442283. PMID 3624481.
- ↑ Sharman, Andrew; Low, James (2008). "Vasopressin and its role in critical care". Continuing Education in Anaesthesia Critical Care & Pain. 8 (4): 134–137. doi:10.1093/bjaceaccp/mkn021. ISSN 1743-1816.
- ↑ Yoong HF, Sundaram MB, Aida Z (2005). "Prevalence of nocturnal polyuria in patients with benign prostatic hyperplasia". Med J Malaysia. 60 (3): 294–6. PMID 16379182.
- ↑ Jin MH, Moon du G (July 2008). "Practical management of nocturia in urology". Indian J Urol. 24 (3): 289–94. doi:10.4103/0970-1591.42607. PMC 2684373. PMID 19468456.
- ↑ Christensen JH, Siggaard C, Rittig S: Autosomal dominant familial neurohypophyseal diabetes insipidus. APMIS Suppl (109):92–95, 2003.
- ↑ Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 16:2836–2846, 2005.
- ↑ Makaryus AN, McFarlane SI: Diabetes insipidus: diagnosis and treatment of a complex disease. Cleve Clin J Med 73:65–71, 2006.
- ↑ Bichet DG: Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol 28:245–251, 2008.
- ↑ Moeller HB, Rittig S, Fenton RA: Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev 34:278–301, 2013.
- ↑ Spira A, Gowrishankar M, Halperin ML: Factors contributing to the degree of polyuria in a patient with poorly controlled diabetes mellitus. American journal of kidney diseases : the official journal of the National Kidney Foundation 1997, 30(6):829-835.
- ↑ Illowsky BP, Kirch DG: Polydipsia and hyponatremia in psychiatric patients. The American journal of psychiatry 1988, 145(6):675-683.
- ↑ Goldman MB, Luchins DJ, Robertson GL: Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. The New England journal of medicine 1988, 318(7):397-403.